ProCE Banner Activity

抗逆转录病毒疗法(ART)治疗艾滋病毒感染:不断发展的理念和创新的策略

在CCO艾滋病年度会议这场热烈的小组讨论中,专家们研讨了抗逆转录病毒疗法的最新进展,包括将治疗简化至二联药物方案、ART在妊娠期间的安全性、与ARV药物相关的体重增加、以及ART的创新策略。

Released: January 05, 2021

Expiration: January 04, 2022

No longer available for credit.

Share

Faculty

Michelle Cespedes

Michelle Cespedes, MD, MS

Professor of Medicine
Division of Infectious Disease
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Gregory Huhn

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

David A. Wohl

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by University of South Florida
ProCE Banner

Supporters

由来自……的教育资助金赞助

Merck Sharp & Dohme Corp.

ViiV Healthcare

Target Audience

该项目的目标受众为医生、临床药剂师、护士以及其他为HIV病毒感染者提供医疗服务的从业人员

Learning Objectives

Upon completion of this activity, participants should be able to:
  • 了解最新临床研究结果和发展中的治疗指南,将其应用于ART一线药物和转换用药方案的时机与用药选择、以及对经治HIV感染者的管理中。
  • 有效预防或管理药物间相互作用、不良事件以及其他与HIV、ART和合并症有关的并发症。

Faculty Disclosure

Primary Author

Michelle Cespedes, MD, MS

Professor of Medicine
Division of Infectious Disease
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Michelle S. Cespedes,医学博士、科学硕士,披露她曾获得吉利德科学和ViiV Healthcare的咨询费用。

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Gregory Huhn,医学博士,公共卫生硕士,声明在其研究中曾得到过吉利德科学、杨森制药、礼来、Proteus数码健康以及ViiV公司提供的资金支持;他曾获得来自礼来和杨森公司的咨询费用,并且曾在吉利德科学、杨森和ViiV的咨询委员会和专门小组内任职。

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

David A. Wohl,医学博士,披露在其研究中曾得到吉利德科学、默克公司、以及ViiV公司提供的资金支持,并曾获得吉利德科学、杨森制药、默克公司、以及ViiV公司的咨询费用。

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette,博士,无相关利益冲突需要声明

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright,博士,无相关利益冲突需要声明

Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain,博士,无相关利益冲突需要声明

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, 硕士,无相关利益冲突需要声明

Anna Poppa,

Managing Editor, HIV
Clinical Care Options, LLC

Anna Poppa无相关利益冲突需要声明

Julie Skowronski, FNP-BC

Julie Skowronski,护士委员会认证家庭护理医师,无相关利益冲突需要声明

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Goal


这项活动通过聚焦HIV治疗领域的最新进展及诊所中遇到的关键问题,旨在加强临床医生解决HIV管理中最重要和最具挑战的问题的能力。